The deal includes a two-year research collaboration with Chun-Ming Huang and his associates at UC San Diego School of Medicine for further research and development.
Further, the financial terms of the agreement were not disclosed.
Sanofi Global Research & Development president Elias Zerhouni said this opportunity could provide an immunotherapeutic product with benefits and a novel mechanism of action to address an unmet medical need.
"This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease," Zerhouni said.